Status:
ENROLLING_BY_INVITATION
Intravitreal and Intracameral DEX in NPDR
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Non-Proliferative Diabetic Retinopathy
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
Detailed Description
The study aims to analyze the impact of intravitreal and intracameral DEX in diabetic patients with NPDR who are undergoing phacoemulsification surgery. Specifically, the investigators will investigat...
Eligibility Criteria
Inclusion
- type 2 diabetic cataracts patients who were diagnosed with mild to moderate NPDR
Exclusion
- \-
Key Trial Info
Start Date :
January 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06951087
Start Date
January 31 2022
End Date
June 1 2025
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Institute, Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 226001